Hisco announced that the company recently received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration. HSK44459 tablets were approved for clinical trials with additional indications. The indication is inflammatory bowel disease. HSK44459 tablets are a new small-molecule drug independently developed by the company to treat inflammatory bowel disease. Preclinical studies have shown clear targets, accurate efficacy, good safety, and broad clinical application prospects. The company will disclose information in a timely manner based on the progress of the project.

Hisco announced that the company recently received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration. HSK44459 tablets were approved for clinical trials with additional indications. The indication is inflammatory bowel disease. HSK44459 tablets are a new small-molecule drug independently developed by the company to treat inflammatory bowel disease. Preclinical studies have shown clear targets, accurate efficacy, good safety, and broad clinical application prospects. The company will disclose information in a timely manner based on the progress of the project.